

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization

International Bureau

(43) International Publication Date
20 September 2018 (20.09.2018)



(10) International Publication Number
WO 2018/167269 A1

(51) International Patent Classification:

C07D 401/14 (2006.01) *C07D 417/12* (2006.01)
C07D 405/14 (2006.01) *C07D 491/18* (2006.01)
C07D 217/04 (2006.01) *C07D 495/04* (2006.01)
C07D 217/06 (2006.01) *A61P 35/00* (2006.01)
C07D 401/12 (2006.01) *A61K 31/4725* (2006.01)
C07D 409/12 (2006.01) *A61K 31/4365* (2006.01)
C07D 409/14 (2006.01)

TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

— with international search report (Art. 21(3))

(21) International Application Number:

PCT/EP2018/056663

(22) International Filing Date:

16 March 2018 (16.03.2018)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

1704327.4 17 March 2017 (17.03.2017) GB

(71) Applicant: ARGONAUT THERAPEUTICS LIMITED

[GB/GB]; The Magdalen Centre, Oxford Science Park, Robert Robinson Avenue, Oxford Oxfordshire OX4 4GA (GB).

(72) Inventors: MORLEY, Andrew; c/o O2h Ventures Limited,

23 Science Park, Cambridge Cambridgeshire CB4 0EY (GB). MILLER, Rebecca; c/o Argonaut Therapeutics Limited, The Magdalen Centre, Oxford Science Park, Robert Robinson Avenue, Oxford Oxfordshire OX4 4GA (GB). LA THANGUE, Nicholas; c/o Argonaut Therapeutics Limited, The Magdalen Centre, Oxford Science Park, Robert Robinson Avenue, Oxford Oxfordshire OX4 4GA (GB).

(74) Agent: HGF LIMITED; 1 City Walk, LEEDS Yorkshire

LS11 9DX (GB).

(81) Designated States (unless otherwise indicated, for every

kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every

kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,

(54) Title: COMPOUNDS USEFUL IN THE TREATMENT OR PREVENTION OF A PRMT5-MEDIATED DISORDER

(57) Abstract: The present disclosure relates to compounds suitable for the inhibition of protein arginine methyl-transferase (PRMT), in particular PRMT5. These compounds may be for use as therapeutic agents, in particular, agents for use in the treatment and/or prevention of proliferative diseases, such as cancer.



WO 2018/167269 A1